Explore our VHH resources
Sign up for our VHH Newsletter and stay in the loop with the latest news, research papers, blog articles.
Appetite for destruction: ‘Plug and play’ targeted protein degradation using synthetic VHH antibodies to take out tricky targets
Novel VHH protein degraders developed using Isogenica’s VHH antibody libraries show anti-tumour activity in vivo.
‘Intrabodies’ – Isogenica’s VHH antibodies improve heart function when delivered intracellularly
Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in Nature Communications. In a step forward for intracellular biotherapeutics, this early stage investigational research also used a viral vector to deliver our VHH antibodies directly inside heart cells.
2-for-1 VHH antibody engineering
When a partner needed VHH antibody engineering fast, we developed a method to humanise and affinity mature the antibodies in a single step.
VHH Humanisation
VHH humanisation can be a challenge. Here, we compare two methods – safe-but-slow rational humanisation and fast-but-risky CDR grafting. We also explore the impact of synthetic versus immune-derived frameworks.
Llamas: leading the pack in new cancer therapy, BioScience Today’s article on Isogenica’s VHH discovery
Llamas: leading the pack in new cancer therapy, BioScience Today’s article on Isogenica’s VHH discovery
Small and mighty – VHH ‘bolt-ons’ to expand therapeutic functionality
Small antibody building blocks: VHHs or “Nanobodies” are single domain antibodies about 1/10th the size of an IgG. Combined with their robust biophysical properties and high solubiltiy, the simplicity of these molecules…
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. Download Extending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD